Okyo Pharma Limited · NASDAQ:OKYO
Okyo Pharma — Investor Presentation (February 2026)
28 slides from Okyo Pharma's investor presentation, Feb 13, 2026
Slide 1: Addressing Unmet Needs in Corneal and Anterior Segment Diseases
Addressing Unmet Needs in Corneal and Anterior Segment Diseases A differentiated therapeutic approach targeting high-value, underserved rare ocular diseases Corporate Highlights | Q1 2026 Nasdaq: OKYO
Slide 2: Disclaimer
Disclaimer By accepting and using this presentation, you will be deemed to agree not to disclose any information contained herein except as may be required by law. Additionally, certain information contained in this presentation has been obtained from published sources prepared by other parties, whi
Slide 3: Ophthalmic Leadership Bridging Scientific Innovation and Value-Creation
Ophthalmic Leadership Bridging Scientific Innovation and Value-Creation Management Team 30+ years domestic 25+ years domestic 35+ years 30+ years of 20+ years of and global and global ophthalmic pharmaceutical and domestic and global finance and ophthalmic medical and clinical biotechnology ophthalm
Slide 4: Pioneering a New Ocular Therapeutic Market with No Approved Options
Pioneering a New Ocular Therapeutic Market with No Approved Options Urcosimod (0.05%) (formally OK-101) Novel, non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for neuropathic corneal pain (NCP) A potentially promising candidate for the treatment
Slide 5: OKYO Development Pipeline
OKYO Development Pipeline = SSSI ESS Neuropathic Corneal Pain (NCP) Phase 2a (n=18) completed; Topline data announced July 2025 Rare Corneal Disease* Uveitis DACA wrconne . . Initiate Phase 2b/3: 2Q26 Topline Data: 1H27 Initiate Phase 2: 1H27 Ongoing Pre-clinical Evaluation
Slide 6: Market Overview
“NX Market Overview
Slide 7: NCP: A Significantly Under-Researched Disease with Substantial Impact on Patient Quality of Life
NCP: A Significantly Under-Researched Disease with Substantial Impact on Patient Quality of Life + Neuropathic corneal pain (NCP) is an ill-defined disease that causes eyes, face, or head sensitivity Light / air sensitivity and pain, often in response to a non-painful stimuli Foreign body sensation
Slide 8: NCP Patient Journey
NCP Patient Journey Initial Presentation ») Referral to Eye Specialist » NCE Diagnosis by More Specialized © © Neuro-ophthalmologist / Corneal Pain Specialist / Rheumatologist / Neurologist PCP, Surgeon*, Rheumatologist, Neurologist Optometrist / Ophthalmologist Patient is evaluated with corneal est
Slide 9: Rising Scrutiny of Gabapentin Highlights Need for Earlier, Targeted NCP Diagnosis
Rising Scrutiny of Gabapentin Highlights Need for Earlier, Targeted NCP Diagnosis Wall Street Journal: “The Hidden Risks of America’s Most Popular Prescription Painkiller” ¢ Gabapentin increasingly prescribed off-label for chronic pain, TREET JOURNAL. despite mixed efficacy * 8 states have reclassif
Slide 10: Urcosimod: Commercial Assessment and Pricing Strategy
Urcosimod: Commercial Assessment and Pricing Strategy NCP Market Characterizati Commercial Opportunity Large, underserved and poorly characterized patient population with no Conduct ECP and payer research evaluating the target product profile (TPP) approved therapies measuring demand and anticipated
Slide 11: Neuropathic Corneal Pain Represents a Severe Unmet Medical Need
Neuropathic Corneal Pain Represents a Severe Unmet Medical Need 66 > “The week | tried your drop, my perspective on my disease changed forever. | was shocked that a drop can take away the type of pain | was feeling. Indescribable pain. It gave me hope. Ever since then, I’ve been trying to tell other
Slide 12: Mechanism of Action & Clinical Rationale
Mechanism of Action & Clinical Rationale
Slide 13: Urcosimod: A Lipid-Conjugated Chemerin Peptide
Urcosimod: A Lipid-Conjugated Chemerin Peptide > First-in-Class chemerin receptor agonist that modulates neuro-immune cross-talk > Dual mechanism of action: targets both immune cell-mediated inflammation and neuronal/glial cell populations in the dorsal root ganglion > Topically active peptide desig
Slide 14: Urcosimod Phase 2 DED Trial
Urcosimod Phase 2 DED Trial > Enrollment: 240 randomized subjects / ~80 per study arm > Treatment arms: 3 (Placebo, OK-101 0.05%, OK-101 0.1%) + Study duration: 85 days (~12 weeks) with 6 scheduled patient visits Phase 2 Randomized, + Clinical sites: Multicenter (U.S.) Placebo-Controlled DED Trial E
Slide 15: No Severe Adverse Events Demonstrated in Phase 2 DED Study (240 Subjects)
No Severe Adverse Events Demonstrated in Phase 2 DED Study (240 Subjects) OK-101 (0.1%) (N = 80) OK-101 (0.05%) (N = 81) Placebo (N = 79) Number of Ocular AEs 7 19 7 Number of Ocular TEAES 6 16 6 Number of Ocular SAEs 0 0 0 Number of Ocular TE-SAEs 0 0 0 Number of Subjects Withdrawn Study Drug due t
Slide 16: Urcosimod Reduced Neuropathic Corneal Pain (NCP) in Mouse Model
Urcosimod Reduced Neuropathic Corneal Pain (NCP) in Mouse Model* Ciliary Ligation Model" Illustrates Urcosimod’s Potential to Reduce Ocular Pain. Ciliary nerve ligation surgery to create the neuropathic corneal pain (NCP) model Long Ciliary Nerve Short Ciliary Nerve ulls Medical Center, Boston (Keny
Slide 17: Urcosimod: NCP Clinical Development Plan
Urcosimod: NCP Clinical Development Plan
Slide 18: Urcosimod Phase 2a NCP Trial Design
Urcosimod Phase 2a NCP Trial Design ENDPOINTS Primary Endpoint (through 12 weeks) Pain (Visual Analog Scale) Secondary Endpoint Ocular Pain by OPAS scores QoL improvement by OPAS. Drop comfort Exploratory Endpoints Change in corneal sensation Change in corneal nerve density and length Presence or ab
Slide 19: Phase 2a NCP Clinical Trial Demonstrated Promising Drug Effect
Phase 2a NCP Clinical Trial Demonstrated Promising Drug Effect Phase 2a, Randomized, Double Masked, Placebo-Controlled Study Assessing Safety and Efficacy for Urcosimod in Subjects with NCP STUDY RESULTS e After 12 weeks of treatment, 75% of per-protocol patients Improvement in 10-point VAS receivin
Slide 20: Pain Scores Across Weeks (VAS Scale; Urcosimod 0.05% vs Placebo)
Pain Scores Across 12 Weeks (VAS Scale; Urcosimod 0.05% vs Placebo) + Higher baseline pain severity was associated with a greater treatment effect of urcosimod versus placebo + Steep decline of pain in just 4 weeks For the Phase 2b/3 study, enrollment will be enriched with moderate to severe patient
Slide 21: Urcosimod (0.05%) Signals Promising Nerve Growth Potential
Urcosimod (0.05%) Signals Promising Nerve Growth Potential Median increases in total nerve fiber count vs. placebo (+2.0, n/0.16 mm’, IQR 0.54 to 3.63) vs. placebo (-1.92, n/0.16 mm?, IQR -2.79 to -0.04) > Median increases in total nerve fiber length vs. placebo (+2.6 mm/mm?, IQR 1.55 to 5.67; p = 0
Slide 22: FDA Endorsed Urcosimod Phase 2b/3 NCP Trial
FDA Endorsed Urcosimod Phase 2b/3 NCP Trial Planned enrollment: ~150 subjects Treatment arms: 3 (Placebo, Urcosimod 0.025%, Urcosimod 0.05%) Subjects per arm: 50 Treatment duration: 12 weeks Visits: 5 scheduled visits Clinical sites: 6-8 centers Phase 2b/3 Randomized, Double-Masked, Placebo- Control
Slide 23: Neuropathic Corneal Pain (NCP) Development Plan
Neuropathic Corneal Pain (NCP) Development Plan IND Cleared by FDA [4 Closed Trial to [V| FDA Type C Meeting for OK-101 to Treat Accelerate Clinical NCP Development Phase 2a Randomized, [V¥| Phase 2a Favorable [_] Initiate Phase 2b/3 Placebo-Controlled 48- NCP Topline Readout Multiple-Dose Study Pat
Slide 24: Urcosimod Patent Protection Through at Least 2039
Urcosimod Patent Protection Through at Least 2039 Composition of Matter: Method of Use (Dry Eye): Use (Neuropathic Pain): Rare Corneal Disease* US 10,233,219 US 11,197,906 US 11,254,720 Issued in US to 2034 (+187 days of Patent Term Extension) Provisional patent filing Issued in US to 2034 with Issu
Slide 25: Fast-Tracking a Potential Therapy for NCP Patients with High Unmet Needs
Fast-Tracking a Potential Therapy for NCP Patients with High Unmet Needs oon a a CLINICAL EVIDENCE « Phase 2a Proof of Concept trial to treat NCP clearly demonstrated a promising drug effect « 5.5-point improvement on a 10-point VAS + 75% of treated patients achieved >80% pain improvement OP BHARMA
Slide 26: Appendix
“NX APPENDIX
Slide 27: Human Trials Performed At Urcosimod (0.05%) and (0.10%) But Only 0.05% Is Found to be Effective... Why?
Human Trials Performed At Urcosimod (0.05%) and (0.10%) But Only 0.05% Is Found to be Effective... Why? ANSWER: Urcosimod is a Micellar Drug in Solution needing to be bioactive in eye at ~37 C « At low concentrations (e.g. 0.05% wt) and at 37 C it exists as discrete micelles and is bioactive. <— Lip
Slide 28: Urcosimod Phase 2 DED Trial Design
Urcosimod Phase 2 DED Trial Design ENDPOINTS Primary Endpoints (through Day 85) Inferior Corneal Staining (Sign) Ocular Discomfort Score (Symptom) Secondary Endpoints Total Conjunctival Staining (Sign) Tear Film Break-up Time (TFBUT) (Sign) Blurred Vision Burning/Stinging Pain Daily Symptom Diary PH